| abstract |
The present invention provides compounds that inhibit PKC-theta. Heterocyclic inhibitors having formula (I) with the variables defined herein are useful for treating inflammatory disorders and other physiological disorders in which the PKC-theta isoform plays a role. In another embodiment of the invention there is provided a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier or diluent. These pharmaceutical compositions can be used, for example, in therapy to treat subjects with inflammatory disorders and diseases and allergic disorders and diseases. |